Orphazyme (Denmark) Today
| ORPHA Stock | DKK 980.00 39.00 3.83% |
Performance5 of 100
| Odds Of DistressLess than 44
|
Orphazyme is trading at 980.00 as of the 1st of December 2024, a 3.83 percent down since the beginning of the trading day. The stock's open price was 1019.0. Orphazyme has about a 44 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Orphazyme AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of December 2023 and ending today, the 1st of December 2024. Click here to learn more.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark. The company has 35.31 M outstanding shares. More on Orphazyme AS
Moving against Orphazyme Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Orphazyme Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Orphazyme's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Orphazyme or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Anders Vadsholt |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Orphazyme AS (ORPHA) is traded on Copenhagen Exchange in Denmark and employs 2 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orphazyme's market, we take the total number of its shares issued and multiply it by Orphazyme's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Orphazyme AS operates under Biotechnology sector and is part of Health Care industry. The entity has 35.31 M outstanding shares.
Orphazyme AS has accumulated about 726.93 M in cash with (602.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.8.
Check Orphazyme Probability Of Bankruptcy
Ownership AllocationOrphazyme owns a total of 35.31 Million outstanding shares. Roughly 90.51 pct. of Orphazyme outstanding shares are held by general public with 1.36 % owned by insiders and only 8.13 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Orphazyme Ownership Details
Orphazyme AS Risk Profiles
Although Orphazyme's alpha and beta are two of the key measurements used to evaluate Orphazyme's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.66 | |||
| Semi Deviation | 3.11 | |||
| Standard Deviation | 4.01 | |||
| Variance | 16.05 |
Orphazyme Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Orphazyme without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Orphazyme Corporate Directors
| Remi Droller | Director | Profile | |
| Anders Hedegaard | Director | Profile | |
| Catherine Moukheibir | Director | Profile | |
| Sten Verland | Director | Profile |
Other Information on Investing in Orphazyme Stock
Orphazyme financial ratios help investors to determine whether Orphazyme Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orphazyme with respect to the benefits of owning Orphazyme security.